Therapeutic strategies for congenital myasthenic syndromes
To date, more than 25 genes have been implicated in the etiology of the congenital myasthenic syndromes (CMS), and an ever-growing phenotypic landscape is now encountered in the CMS clinic. Unlike the autoimmune form of myasthenia, there is no role for immunomodulatory agents in the treatment of CMS...
Principais autores: | Lee, M, Beeson, D, Palace, J |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
Wiley
2018
|
Registros relacionados
-
The congenital myasthenic syndromes.
por: Palace, J, et al.
Publicado em: (2008) -
Congenital myasthenic syndromes.
por: Beeson, D, et al.
Publicado em: (1997) -
Congenital myasthenic syndromes: an update.
por: Finlayson, S, et al.
Publicado em: (2013) -
Congenital myasthenic syndromes and the neuromuscular junction.
por: Cruz, P, et al.
Publicado em: (2014) -
The neuromuscular junction and wide heterogeneity of congenital myasthenic syndromes
por: Rodríguez Cruz, P, et al.
Publicado em: (2018)